Publications 2022

Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK (2022)
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Lancet Rheumatol (in press)
DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604

Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA (2022)
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
BMC Med, 20 (1), 378
DOI 10.1186/s12916-022-02587-8, PubMed 36199139

Hinke DM, Andersen TK, Gopalakrishnan RP, Skullerud LM, Werninghaus IC, Grødeland G, Fossum E, Braathen R, Bogen B (2022)
Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses
Cell Rep, 39 (9), 110901
DOI 10.1016/j.celrep.2022.110901, PubMed 35649357

Keresztes G, Baer M, Alfenito MR, Verwoerd TC, Kovalchuk A, Wiebe MG, Andersen TK, Saloheimo M, Tchelet R, Kensinger R, Grødeland G, Emalfarb M (2022)
The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines
Vaccines (Basel), 10 (2)
DOI 10.3390/vaccines10020148, PubMed 35214607

Mahalingam S, Grødeland G (2022)
[Menstrual abnormalities after COVID-19 vaccination]
Tidsskr Nor Laegeforen, 142 (9)
DOI 10.4045/tidsskr.22.0217, PubMed 35699538

Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL (2022)
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002417, PubMed 36328399

Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL (2022)
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355

Søraas A, Grødeland G, Granerud BK, Ueland T, Lind A, Fevang B, Murphy SL, Huse C, Nygaard AB, Steffensen AK, Al-Baldawi H, Holberg-Petersen M, Andresen LL, Ågnes C, Ranheim T, Schanke Y, Istre M, Dahl JA, Chopra A, Dudman S, Kaarbø M, Andersen JT, Vaage EB, Tran TT, Vaage JT et al. (2022)
Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
Front Immunol, 13, 964525
DOI 10.3389/fimmu.2022.964525, PubMed 36159859

Vaksdal HH, Grødeland G (2022)
[Efficacy of three doses of COVID-19 vaccine]
Tidsskr Nor Laegeforen, 142 (5)
DOI 10.4045/tidsskr.22.0096, PubMed 35324133

Publications 2021

Andersen TK, Bodin J, Oftung F, Bogen B, Mjaaland S, Grødeland G (2021)
Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
Front Immunol, 12, 747032
DOI 10.3389/fimmu.2021.747032, PubMed 34691056

Andersen TK, Grødeland G (2021)
[The vaccines can keep up with the SARS-CoV-2 mutations]
Tidsskr Nor Laegeforen, 141 (3)
DOI 10.4045/tidsskr.21.0080, PubMed 33624975

Ianevski A, Yao R, Lysvand H, Grødeland G, Legrand N, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov DE (2021)
Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
Viruses, 13 (9)
DOI 10.3390/v13091768, PubMed 34578348

Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, Yang J, Ravlo E, Wang W, Lysvand H, Løseth K, Oksenych V, Tenson T, Windisch MP, Poranen MM, Nieminen AI, Nordbø SA, Fenstad MH, Grødeland G, Aukrust P, Trøseid M, Kantele A, Lastauskienė E, Vitkauskienė A, Legrand N et al. (2021)
Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections
Viruses, 13 (12)
DOI 10.3390/v13122489, PubMed 34960758

Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, Jørgensen KK, Jahnsen J, Kro GB, Warren DJ, Vaage EB, Kvien TK, Nissen-Meyer LH, Anderson AM, Grødeland G, Haavardsholm EA, Vaage JT, Mjaaland S, Syversen SW, Lund-Johansen F, Munthe LA, Goll GL (2021)
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Lancet Rheumatol, 4 (3), e177-e187
DOI 10.1016/S2665-9913(21)00394-5, PubMed 34977602

Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, Romano M, Barbezange C, Maes P, Van Holm B, Mendoza J, Oyonarte S, Fomsgaard A, Lassaunière R, Zusinaite E, Resman Rus K, Avšič-Županc T, Reimerink JH, Brouwer F, Hoogerwerf M, Reusken CB, Grodeland G, Le Cam S, Gallian P, Amroun A et al. (2021)
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
Euro Surveill, 26 (27)
DOI 10.2807/1560-7917.ES.2021.26.27.2100568, PubMed 34240697

Vaksdal HH, Grødeland G (2021)
[How effective is the COVID-19 vaccine for older persons?]
Tidsskr Nor Laegeforen, 141 (18)
DOI 10.4045/tidsskr.21.0748, PubMed 34911279

Zhou F, Hansen L, Pedersen G, Grødeland G, Cox R (2021)
Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
Front Immunol, 12, 747774
DOI 10.3389/fimmu.2021.747774, PubMed 34887855

Publications 2020

Grødeland G, Baranowska-Hustad M, Abadejos J, Blane TR, Teijaro J, Nemazee D, Bogen B (2020)
Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin
Front Immunol, 11, 431
DOI 10.3389/fimmu.2020.00431, PubMed 32269566

Taxt AM, Grødeland G, Lind A, Müller F (2020)
Status of COVID-19 vaccine development
Tidsskr Nor Laegeforen, 140 (13)
DOI 10.4045/tidsskr.20.0676, PubMed 32998488

Publications 2019

Andersen TK, Huszthy PC, Gopalakrishnan RP, Jacobsen JT, Fauskanger M, Tveita AA, Grødeland G, Bogen B (2019)
Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
NPJ Vaccines, 4, 9
DOI 10.1038/s41541-019-0101-0, PubMed 30775000

Grodeland G, Fossum E, Bogen B (2019)
Targeting of HA to chemokine receptors induces strong and cross-reactive T cell responses after DNA vaccination in pigs
Vaccine, 38 (6), 1280-1285
DOI 10.1016/j.vaccine.2019.11.084, PubMed 31836256

Mooij P, Grødeland G, Koopman G, Andersen TK, Mortier D, Nieuwenhuis IG, Verschoor EJ, Fagrouch Z, Bogers WM, Bogen B (2019)
Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza
Vaccine, 37 (6), 817-826
DOI 10.1016/j.vaccine.2018.12.049, PubMed 30638800

Publications 2018

Anderson AM, Baranowska-Hustad M, Braathen R, Grodeland G, Bogen B (2018)
Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza
J Immunol, 200 (6), 2057-2066
DOI 10.4049/jimmunol.1701088, PubMed 29427414

Braathen R, Spång HCL, Lindeberg MM, Fossum E, Grødeland G, Fredriksen AB, Bogen B (2018)
The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules
Immunohorizons, 2 (1), 38-53
DOI 10.4049/immunohorizons.1700038, PubMed 31022690

Publications 2017

Andersen TK, Zhou F, Cox R, Bogen B, Grødeland G (2017)
A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza
J Virol, 91 (23)
DOI 10.1128/JVI.01340-17, PubMed 28931687

Publications 2016

Grodeland G, Fredriksen AB, Løset GÅ, Vikse E, Fugger L, Bogen B (2016)
Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination
J Immunol, 197 (9), 3575-3585
DOI 10.4049/jimmunol.1600893, PubMed 27671110

Lambert L, Kinnear E, McDonald JU, Grodeland G, Bogen B, Stubsrud E, Lindeberg MM, Fredriksen AB, Tregoning JS (2016)
DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8(+) T Cell Responses, Enabling Faster Resolution of Influenza Disease
Front Immunol, 7, 321
DOI 10.3389/fimmu.2016.00321, PubMed 27602032

Publications 2015

Baranowska M, Hauge AG, Hoornaert C, Bogen B, Grødeland G (2015)
Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza
Vaccine, 33 (49), 6988-96
DOI 10.1016/j.vaccine.2015.08.094, PubMed 26387432

Grødeland G, Bogen B (2015)
Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules
Expert Rev Vaccines, 14 (6), 805-14
DOI 10.1586/14760584.2015.1029919, PubMed 25818107

Grødeland G, Fossum E, Bogen B (2015)
Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines
Front Immunol, 6, 367
DOI 10.3389/fimmu.2015.00367, PubMed 26257735

Publications 2014

Fossum E, Grødeland G, Terhorst D, Tveita AA, Vikse E, Mjaaland S, Henri S, Malissen B, Bogen B (2014)
Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus
Eur J Immunol, 45 (2), 624-35
DOI 10.1002/eji.201445080, PubMed 25410055

Publications 2013

Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B (2013)
DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza
J Immunol, 191 (6), 3221-31
DOI 10.4049/jimmunol.1300504, PubMed 23956431

Grødeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B (2013)
The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype
PLoS One, 8 (11), e80008
DOI 10.1371/journal.pone.0080008, PubMed 24244595

Publications 2010

Ruffini PA, Grødeland G, Fredriksen AB, Bogen B (2010)
Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines
Vaccine, 29 (2), 191-9
DOI 10.1016/j.vaccine.2010.10.057, PubMed 21055498

Publications 2009

Huang TS, Grodeland G, Sleire L, Wang MY, Kvalheim G, Laerum OD (2009)
Induction of circadian rhythm in cultured human mesenchymal stem cells by serum shock and cAMP analogs in vitro
Chronobiol Int, 26 (2), 242-57
DOI 10.1080/07420520902766025, PubMed 19212839

Publications 2007

Grødeland G (2007)
Induction of gene expression and clock-related proteins in serum shocked primary human mesenchymal stem cells in culture
[G. Grødeland], Bergen, VIII, 72 bl.
BIBSYS 071274251